Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
ENTITY
Ascletis Pharma Inc (1672 HK)
Watchlist
68
Analysis
Health Care
•
China
Ascletis Pharma Inc. operates as a biotechnology company. The Company develops and discovers anti-viral drugs to address unmet medical needs in anti-viral, cancer, and fatty liver disease. Ascletis Pharma offers its services worldwide.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Shanghai Henlius Biotech
•
22 Dec 2024 22:02
Henlius (2696 HK): Interesting Shareholder Movements with the Vote on 22 January
Key shareholders will be supportive, and this is a done deal. At the last close, the gross/annualised spread for a 15 February payment was 2.9%...
Arun George
Follow
281 Views
Share
bearish
•
HighTide Therapeutics
•
14 Dec 2023 08:55
Pre-IPO HighTide Therapeutics (PHIP Updates) - Some Shareholders Have Chosen to Quit in Advance
Due to cash shortages and uncertainty in R&D/commercialization, HighTide faces big risks. Many original shareholders cashed out in advance,...
Xinyao (Criss) Wang
Follow
374 Views
Share
bearish
•
HighTide Therapeutics
•
11 Jul 2023 08:55
Pre-IPO HighTide Therapeutics - Its Outlook in NASH Field Is Not Optimistic, with High Risks
Intercept's failure to obtain FDA approval for NASH drug may cast shadow on HighTide's core product outlook.HighTide's valuation performance is...
Xinyao (Criss) Wang
Follow
331 Views
Share
bullish
•
Legend Biotech Corp
•
26 Jul 2022 11:44
Legend Biotech Follow-On - A Little Opportunistic. Last Deal Did Well, After a Large Correction
Legend Biotech Corp (LEGN US), a non-wholly owned subsidiary of Hong Kong-listed Genscript Biotech (1548 HK), is planning to raise up to US$250m in...
Sumeet Singh
Follow
317 Views
Share
bearish
•
Thematic (Sector/Industry)
•
10 Feb 2022 09:05
Would the Cheap Versions of Oral COVID-19 Antiviral Bring New Opportunities for Chinese Companies?
Some Chinese companies are allowed to make cheap versions of Merck’s molnupiravir based on the MPP agreement.We analyzed the impact and outlook,...
Xinyao (Criss) Wang
Follow
242 Views
Share
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.44.3
x